Ultragenyx Pharmaceutical (RARE) Revenue (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) has 11 years of Revenue data on file, last reported at $136.0 million in Q1 2026.

• Quarterly Revenue fell 2.16% year-over-year to $136.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $669.7 million (up 13.48% YoY) and the FY2025 annual result came in at $673.0 million, up 20.18% from the prior year.
• Revenue fell to $136.0 million in Q1 2026 per RARE's latest filing, from $207.3 million in the prior quarter.
• Across five years, Revenue topped out at $207.3 million in Q4 2025 and bottomed at $79.9 million in Q1 2022.
• The 5-year median for Revenue is $127.1 million (2023), against an average of $127.4 million.
• The widest annual swing landed in 2022, when Revenue slipped 19.58%; it then surged 42.27% in 2024.
• Tracing RARE's Revenue over 5 years: stood at $103.3 million in 2022, then rose by 23.02% to $127.1 million in 2023, then increased by 29.5% to $164.6 million in 2024, then climbed by 25.89% to $207.3 million in 2025, then slumped by 34.39% to $136.0 million in 2026.
• Per Business Quant, the three latest RARE Revenue figures stand at $136.0 million (Q1 2026), $207.3 million (Q4 2025), and $159.9 million (Q3 2025).

Peer Comparison